PDCD1 and cancer: In conclusion, the durable, systemic antitumor activity and acceptable safety profile demonstrated in this phase 1b study support further clinical development of vidutolimod in combination with PD‐1 blockade to target cancer immune evasion and overcome PD‐1 blockade resistance.